Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
immune disease treatment ?from Chinese biotech firm TJ Biopharma, giving the U.S. drugmaker worldwide rights to develop ?and market the treatment. • Shares of Biogen were up 1.3% in premarket trading. • Under the agreement, TJ Bio will receive $100 million upfront and could get up to $750 million in commercial and sales milestone payments, ?plus royalties on sales ?in Greater China. • The drug, felzartamab, is being studied in late-stage trials in several immune-related diseases, including ?IgA nephropathy and primary membranous nephropathy, which damage the kidneys and can lead to organ failure. • Biogen acquired the drug through an up ?to $1.8 billion ?buyout of Human Immunology Biosciences (HI-Bio) ?in 2024. • HI-Bio had licensed ?the global rights to develop and commercialize felzartamab, except in Greater China, from MorphoSys, a Novartis unit. • Biogen said it would also take over milestone payment and royalty obligations tied to the agreement with MorphoSys. • The
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Assessing Novartis (SWX:NOVN) Valuation After Recent Share Price Moves And Long Term Returns [Yahoo! Finance]Yahoo! Finance
- String of scientist deaths, vanishings fuels expert talks of shadow ops and silenced secrets: 'Very serious' [FOX News]FOX News
- Biotechnology Expands in Southern California [Los Angeles Times (CA)]Los Angeles Times
- Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026 [Yahoo! Finance]Yahoo! Finance
- Missing general, scientist deaths tied to secret US work prompt White House probe [FOX News]FOX News
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website